Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioray Biotech CoROCO:7561 81 EV-to-FCF is 6.08 as of Jul. 20, 2026. GuruFocus rates ROCO:7561 with a GF Score™ of 81/100 and a GF Value™ of NT$29.52 (Significantly Undervalued). Among 565 Drug Manufacturers companies, Bioray Biotech Co ranks better than 87.43% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bioray Biotech Co's Enterprise Value is NT$433.1 Mil.
Bioray Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$71.2 Mil. Therefore, Bioray Biotech Co's EV-to-FCF for today is 6.08.
The historical rank and industry rank for Bioray Biotech Co's EV-to-FCF or its related term are showing as below:
ROCO:7561'
s EV-to-FCF Range Over the Past 10 Years
Min: -633.97 Med: -15.37 Max: 59.89
Current: 6.08
During the past 9 years, the highest EV-to-FCF of Bioray Biotech Co was 59.89. The lowest was -633.97. And the median was -15.37.
ROCO:7561's EV-to-FCF is ranked better than 87.43% of 565
companies
in the Drug Manufacturers industry
Industry Median: 20.96
vs ROCO:7561: 6.08
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bioray Biotech Co (ROCO:7561) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bioray Biotech Co's PE Ratio (TTM) for today is calculated as:
Bioray Biotech Co's share price for today is NT$20.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bioray Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.090.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bioray Biotech Co EV-to-FCF Related Terms
Bioray Biotech Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bioray Biotech Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bioray Biotech Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioray Biotech Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bioray Biotech Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bioray Biotech Co's EV-to-FCF falls into.
Bioray Biotech Co's current Enterprise Value is NT$433.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bioray Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$71.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioray Biotech Co (ROCO:7561) has a EV-to-FCF of 6.08 as of Jul. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bioray Biotech Co and its competitors. According to the industry distribution chart, Bioray Biotech Co ranks #71 out of 565 companies in the Drug Manufacturers industry, placing it in the top 12.6%.
Is Bioray Biotech Co's EV-to-FCF too high?
Bioray Biotech Co's current EV-to-FCF is 6.08. The Drug Manufacturers industry median EV-to-FCF is 20.96. Bioray Biotech Co's value of 6.08 is 71% below this industry median. Based on the distribution chart, Bioray Biotech Co ranks #71 out of 565 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bioray Biotech Co has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioray Biotech Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bioray Biotech Co ranks #71 out of 565 companies for EV-to-FCF. This places Bioray Biotech Co in the top 13% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.96. Bioray Biotech Co's value of 6.08 is 71% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioray Biotech Co's current EV-to-FCF of 6.08 is 71% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bioray Biotech Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioray Biotech Co's current EV-to-FCF is 6.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioray Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Bioray Biotech Co (ROCO:7561) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$29.52, compared to a current price of NT$20.00 — trading 32.2% below its estimated fair value. The current EV-to-FCF is 6.08 and 71% below the Drug Manufacturers industry median of 20.96. Bioray Biotech Co's overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bioray Biotech Co (ROCO:7561), the current EV-to-FCF is 6.08 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioray Biotech Co (ROCO:7561) Overvalued in 2026?
Based on GuruFocus' analysis, Bioray Biotech Co stock appears to be undervalued.
The current stock price of NT$20.00 is trading 32.2% below its estimated GF Value™ of NT$29.52.
GuruFocus considers Bioray Biotech Co to be Significantly Undervalued.
Key valuation signals for ROCO:7561:
EV-to-FCF: 6.08
GF Value™: NT$29.52 vs. price of NT$20.00 (32.2% below fair value)
Industry Position: 71% below the Drug Manufacturers median (#71 of 565)
No single metric tells the full story. See the ROCO:7561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioray Biotech Co Ltd is engaged in the development and manufacturing of biological agents, including functional probiotics, medicinal fungi, and immune cell preparations.
81GF Score
Get the complete analysis for ROCO:7561
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7561 has been successfully added to your 
